MedTrace Logo

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

NCT05313828 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-04-06

No results posted yet for this study

Summary

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections\]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK.

In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

Conditions

  • Corneal Ulcer

Interventions

DRUG

Acyclovir

acyclovir 4 times /day

DRUG

Tobramycin

tobramycin 4 times /day

DRUG

Fluorometholone

Fluorometholone 4 times/ day

DRUG

Sodium Hyaluronate

Sodium Hyaluronate 4 times/day

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-18
Primary Completion
2022-06-28
Completion
2022-07-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05313828 on ClinicalTrials.gov